Form D · Biotechnology
Arrakis Therapeutics, Inc.
Waltham, MA · CIK 0001699493
Offering snapshot reported Apr 18, 2019 · SEC filing
- Reported sold
- $15M Offering amount: $75M
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 15, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 18, 2019 | Initial | $14,999,992 | No comparison | 15 | SEC filing |
| Mar 2, 2017 | Initial | $13,238,466 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-337635
Source: Form D, filed Apr 18, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Colleen Cuffaro | Director |
| Richard Gaster | Director |
| Michael Gilman | Director, Executive |
| Carolyn Green | Director |
| Jakob Loven | Director |
| David Neafus | Executive |
| Raj Parekh | Director |
| Russell C. Petter | Executive |
| Nikola Trbovic | Director |
| Alan E. Walts | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
830 Winter Street
Waltham, MA, 02451
Waltham, MA, 02451